Permanent neonatal diabetes mellitus in monozygotic twins achieving low-dose sulfonylurea therapy

Kelly A. Hicks, Jake A. Kushner, Rubina Heptulla, J. Nina Ham

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Although KCNJ11 mutations of the KATP channel within the β cell are known to prevent insulin secretion and cause permanent neonatal diabetes mellitus, the genotype-phenotype correlation continues to be of clinical interest. We report the clinical outcomes in monozygotic twins with neonatal diabetes due to heterozygous mutations in KCNJ11 at R201H. The twins demonstrated concordant clinical outcomes after transitioning from insulin to oral sulfonylurea therapy at 4 months of age. Both twins remained on sulfonylurea therapy while achieving similar growth, development, and metabolic goals. They exhibit marked sensitivity to sulfonylurea therapy with current dosing at 0.05 and 0.06 mg/kg per day at age 5 years which deviates from the approximate maintenance dose of 0.4 mg/kg per day at the time of transition and subsequent follow-up. Metabolic control provided by low-dose sulfonylurea therapy is likely due to early age at transition from insulin to sulfonylurea therapy and possible preservation of endogenous insulin secretion.

Original languageEnglish (US)
Pages (from-to)135-138
Number of pages4
JournalJournal of Pediatric Endocrinology and Metabolism
Volume27
Issue number1-2
DOIs
StatePublished - Jan 2014

Fingerprint

Monozygotic Twins
Insulin
Therapeutics
KATP Channels
Mutation
Genetic Association Studies
Growth and Development
Permanent Neonatal Diabetes Mellitus

Keywords

  • Diabetes mellitus
  • KCNJ11
  • Neonatal diabetes
  • Permanent neonatal diabetes
  • Sulfonylureas

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology, and Child Health

Cite this

Permanent neonatal diabetes mellitus in monozygotic twins achieving low-dose sulfonylurea therapy. / Hicks, Kelly A.; Kushner, Jake A.; Heptulla, Rubina; Ham, J. Nina.

In: Journal of Pediatric Endocrinology and Metabolism, Vol. 27, No. 1-2, 01.2014, p. 135-138.

Research output: Contribution to journalArticle

Hicks, Kelly A. ; Kushner, Jake A. ; Heptulla, Rubina ; Ham, J. Nina. / Permanent neonatal diabetes mellitus in monozygotic twins achieving low-dose sulfonylurea therapy. In: Journal of Pediatric Endocrinology and Metabolism. 2014 ; Vol. 27, No. 1-2. pp. 135-138.
@article{827a66f6d1bd429a96b6981cc4186d9f,
title = "Permanent neonatal diabetes mellitus in monozygotic twins achieving low-dose sulfonylurea therapy",
abstract = "Although KCNJ11 mutations of the KATP channel within the β cell are known to prevent insulin secretion and cause permanent neonatal diabetes mellitus, the genotype-phenotype correlation continues to be of clinical interest. We report the clinical outcomes in monozygotic twins with neonatal diabetes due to heterozygous mutations in KCNJ11 at R201H. The twins demonstrated concordant clinical outcomes after transitioning from insulin to oral sulfonylurea therapy at 4 months of age. Both twins remained on sulfonylurea therapy while achieving similar growth, development, and metabolic goals. They exhibit marked sensitivity to sulfonylurea therapy with current dosing at 0.05 and 0.06 mg/kg per day at age 5 years which deviates from the approximate maintenance dose of 0.4 mg/kg per day at the time of transition and subsequent follow-up. Metabolic control provided by low-dose sulfonylurea therapy is likely due to early age at transition from insulin to sulfonylurea therapy and possible preservation of endogenous insulin secretion.",
keywords = "Diabetes mellitus, KCNJ11, Neonatal diabetes, Permanent neonatal diabetes, Sulfonylureas",
author = "Hicks, {Kelly A.} and Kushner, {Jake A.} and Rubina Heptulla and Ham, {J. Nina}",
year = "2014",
month = "1",
doi = "10.1515/jpem-2013-0171",
language = "English (US)",
volume = "27",
pages = "135--138",
journal = "Journal of Pediatric Endocrinology and Metabolism",
issn = "0334-018X",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "1-2",

}

TY - JOUR

T1 - Permanent neonatal diabetes mellitus in monozygotic twins achieving low-dose sulfonylurea therapy

AU - Hicks, Kelly A.

AU - Kushner, Jake A.

AU - Heptulla, Rubina

AU - Ham, J. Nina

PY - 2014/1

Y1 - 2014/1

N2 - Although KCNJ11 mutations of the KATP channel within the β cell are known to prevent insulin secretion and cause permanent neonatal diabetes mellitus, the genotype-phenotype correlation continues to be of clinical interest. We report the clinical outcomes in monozygotic twins with neonatal diabetes due to heterozygous mutations in KCNJ11 at R201H. The twins demonstrated concordant clinical outcomes after transitioning from insulin to oral sulfonylurea therapy at 4 months of age. Both twins remained on sulfonylurea therapy while achieving similar growth, development, and metabolic goals. They exhibit marked sensitivity to sulfonylurea therapy with current dosing at 0.05 and 0.06 mg/kg per day at age 5 years which deviates from the approximate maintenance dose of 0.4 mg/kg per day at the time of transition and subsequent follow-up. Metabolic control provided by low-dose sulfonylurea therapy is likely due to early age at transition from insulin to sulfonylurea therapy and possible preservation of endogenous insulin secretion.

AB - Although KCNJ11 mutations of the KATP channel within the β cell are known to prevent insulin secretion and cause permanent neonatal diabetes mellitus, the genotype-phenotype correlation continues to be of clinical interest. We report the clinical outcomes in monozygotic twins with neonatal diabetes due to heterozygous mutations in KCNJ11 at R201H. The twins demonstrated concordant clinical outcomes after transitioning from insulin to oral sulfonylurea therapy at 4 months of age. Both twins remained on sulfonylurea therapy while achieving similar growth, development, and metabolic goals. They exhibit marked sensitivity to sulfonylurea therapy with current dosing at 0.05 and 0.06 mg/kg per day at age 5 years which deviates from the approximate maintenance dose of 0.4 mg/kg per day at the time of transition and subsequent follow-up. Metabolic control provided by low-dose sulfonylurea therapy is likely due to early age at transition from insulin to sulfonylurea therapy and possible preservation of endogenous insulin secretion.

KW - Diabetes mellitus

KW - KCNJ11

KW - Neonatal diabetes

KW - Permanent neonatal diabetes

KW - Sulfonylureas

UR - http://www.scopus.com/inward/record.url?scp=84893728497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893728497&partnerID=8YFLogxK

U2 - 10.1515/jpem-2013-0171

DO - 10.1515/jpem-2013-0171

M3 - Article

C2 - 23959658

AN - SCOPUS:84893728497

VL - 27

SP - 135

EP - 138

JO - Journal of Pediatric Endocrinology and Metabolism

JF - Journal of Pediatric Endocrinology and Metabolism

SN - 0334-018X

IS - 1-2

ER -